Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Yescarta

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approves Label Update For Kite's Yescarta® In Cns Lymphoma
    FDA Approves Label Update For Kite's Yescarta® In Cns Lymphoma

    06 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260205203420/en/FDA-Approves-Label-Update-for-Kites-Yescarta-for-RelapsedRefractory-Primary-Central-Nervous-System-Lymphoma

    BUSINESSWIRE
    06 Feb 2026
    Share Share
    Yescarta® Shows Consistent Benefits in R/R LBCL at ASH 2025
    Yescarta® Shows Consistent Benefits in R/R LBCL at ASH 2025

    07 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251207097497/en/Yescarta-Delivers-Consistent-Safety-Efficacy-and-Quality-of-Life-Benefits-Across-Broad-Range-of-RelapsedRefractory-Large-B-cell-Lymphoma-Patients-in-New-Analysis-at-ASH-2025

    BUSINESSWIRE
    07 Dec 2025
    Share Share
    Kite Shows Yescarta Data for Outpatient Lymphoma Care at ASCO
    Kite Shows Yescarta Data for Outpatient Lymphoma Care at ASCO

    01 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250601431400/en/Kite-Presents-New-Real-World-Data-Supporting-Use-of-Potentially-Curative-Yescarta-in-Outpatient-Care-Setting-for-Patients-with-RelapsedRefractory-Large-B-Cell-Lymphoma-at-ASCO-2025

    BUSINESSWIRE
    01 Jun 2025
    Share Share
    Kite's Yescarta® Shows Durable Response in Relapsed Lymphomas
    Kite's Yescarta® Shows Durable Response in Relapsed Lymphomas

    09 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241209207499/en

    BUSINESSWIRE
    09 Dec 2024
    Share Share
    Kite Presents Yescarta Data For Earlier Treatment Lines
    Kite Presents Yescarta Data For Earlier Treatment Lines

    14 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240614729632/en

    BUSINESSWIRE
    14 Jun 2024
    Share Share
    Poseida examines CAR-T conditioning to crack into solid tumors
    Poseida examines CAR-T conditioning to crack into solid tumors

    10 Apr 2024

    // Annalee Armstrong FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/aacr-bring-car-t-solid-tumors-poseida-thinks-we-need-boost-conditioning-therapy

    Annalee Armstrong FIERCE BIOTECH
    10 Apr 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.